Article Text

FRI0226 Rituximab versus abatacept in rheumatoid arthritis patients with an inadequate response to prior biologic therapy: a retrospective single-center study
  1. E. Keystone1,
  2. D. Weber1,
  3. J. Xiong1,
  4. Y. Sun1,
  5. A. Grant1
  1. 1Mount Sinai Hospital, Toronto, Canada


Background Patients with RA who experience an inadequate response to TNF inhibitor (TNFi) therapy (TNF-IR) may be successfully treated using an alternative TNFi or a biologic with a different mode of action such as rituximab (RTX) or abatacept (ABA). The relative effectiveness of these approaches has not been determined in head-to-head trials. Evidence from real-world experience would help to guide treatment decisions for TNF-IR patients.

Objectives To evaluate the relative effectiveness of RTX and ABA in patients who failed at least one TNF inhibitor.

Methods This was a retrospective chart review of patients from a single site (Rebecca MacDonald Center) with ACR-defined RA who initiated RTX or ABA after failure of at least one TNFi. The relative effectiveness of RTX and ABA was evaluated by analyzing drug survival distribution. Kaplan-Meier survival curves were compared using the log rank test (p-values <0.05 indicated statistical significance).

Results The study cohort comprised 61 patients, of whom 37 and 24 were treated with RTX and ABA, respectively. In the RTX group, 10 patients had also received prior therapy with ABA. Demographics and disease characteristics were generally similar in the two groups, although RTX patients had higher disease activity compared with ABA patients (mean CDAI: RTX 32.5 vs. ABA 26.9) and had received more prior TNFis (1.8 vs. 1.7) and/or ABA (2.1 vs. 1.7). After excluding the RTX patients who had received prior ABA, survival rates over time were generally better with RTX vs. ABA. Estimated survival rates at time 1.0, 2.0, 3.0 and 4.0 years were 0.79, 0.68, 0.68, and 0.68 for RTX and 0.74, 0.54, 0.54, and 0.41 for ABA. Overall, survival distribution was not significantly different between the RTX and ABA groups (p=0.658); however, RTX patients who had also failed ABA had significantly reduced survival compared with those who had not received ABA (p=0.015).

Stratification of survival data according to number of prior TNFi failures indicated that RTX (exluding patients with prior ABA) was superior to ABA among patients who had failed 3 TNFis. Survival was also numerically greater with RTX vs. ABA in patients who had failed 1 prior TNFi.

Conclusions These results from real-life practice suggest that in RA patients who failed one or more TNFi, RTX may have better long-term survival than either ABA or an alternative TNFi. Prior ABA appears to reduce RTX efficacy. Further data are needed.

Disclosure of Interest: None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.